Analyze the impact of 6 analyst ratings on Aclaris Therapeutics ACRS within the last quarter:

Within the last quarter, 6 analysts provided 12-month price targets for Aclaris Therapeutics. The average target is $19.17, with a high estimate of $43.00 and a low estimate of $1.00.

Discover a summary of 6 analysts' ratings for Aclaris Therapeutics over the last 3 months. Increased bullish ratings indicate a positive sentiment, while increased bearish ratings signal a negative outlook.

This current average has decreased by 11.54% from the previous average price target of $21.67.

Breaking Down Analyst Ratings: A Detailed Examination

Explore the analyses of financial experts and analysts, gaining insights into their recent assessments for Aclaris Therapeutics. The Ratings Table below delivers a detailed overview of the actions undertaken by key analysts, their current ratings, and price targets. Uncover valuable perspectives on possible market trends and investor sentiment by understanding the perceptions of these experts towards the company.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Aclaris Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aclaris Therapeutics compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Aclaris Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Aclaris Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics's Economic Impact: An Analysis

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Aclaris Therapeutics faced challenges, resulting in a decline of approximately -51.19% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Aclaris Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -315.24%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -17.41%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Aclaris Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -12.89%, the company showcases efficient use of assets and strong financial health.

Debt Management: Aclaris Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.

Understanding the Relevance of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.